NEUROGENE INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 33.21 USD | +0.94% |
|
-6.16% | +71.36% |
Presenter SpeechGreg Harrison (Analysts)Hi, everyone. Welcome to the second day of the virtual...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Neurogene Inc. is a clinical-stage biotechnology company. The Company, through its proprietary transgene regulation technology, Expression Attenuation via Construct Tuning (EXACT), is building a product portfolio of genetic medicines for rare neurological diseases with high unmet needs not otherwise addressable by conventional gene therapy. Its clinical-stage program, NGN-401, utilize the EXACT platform, which is under development for the treatment of Rett syndrome, a disease with a patient population that has a significant unmet need, and that ultimately progresses to substantial neurological and physical impairment and premature death. NGN-401 is being evaluated in pediatric female patients with Rett syndrome in a Phase 1/2 open-label, multi-center clinical trial that assesses the safety, tolerability, and efficacy of two doses of NGN-401 delivered using a one-time intracerebral ventricular (ICV) procedure. It is also developing NGN-101 for the treatment of CLN5 Batten disease.
Calendar
2024-06-14
- Annual General Meeting
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
33.21
USD
Average target price
51.5
USD
Spread / Average Target
+55.07%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +71.36% | 427M | |
| +23.37% | 47.02B | |
| +49.28% | 41.86B | |
| -0.94% | 41.76B | |
| -5.86% | 28.8B | |
| +11.29% | 26.05B | |
| -20.92% | 19.15B | |
| +3.20% | 12.55B | |
| -2.67% | 11.82B | |
| +30.23% | 12.34B |
- Stock Market
- Equities
- NGNE Stock
- News Neurogene Inc.
- Transcript : Neoleukin Therapeutics, Inc. Presents at BofA Securities 2021 Virtual Health Care Conference, May-12-2021 10